利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.023 秒)

    RISK MARKERS FOR CARDIOVASCULAR DISEASE
    1.
    发明申请
    RISK MARKERS FOR CARDIOVASCULAR DISEASE 有权
    心血管疾病危险标志

    公开(公告)号：US20130177551A1

    公开(公告)日：2013-07-11

    申请号：US13683527

    申请日：2012-11-21

    申请人： Stanley L. Hazen ,  Michael Kinter ,  Marc S. Penn ,  Jonathan Smith ,  Lemin Zheng

    发明人： Stanley L. Hazen ,  Michael Kinter ,  Marc S. Penn ,  Jonathan Smith ,  Lemin Zheng

    IPC分类号： G01N33/92

    CPC分类号： G01N33/561 ,  C07K16/18 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/775 ,  G01N2800/32

    摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

    摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-I相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。

    USE OF TMAVA ANTAGONIST AND SYSTEM FOR DIAGNOSING FATTY LIVER OR HEART FAILURE
    2.
    发明申请
    USE OF TMAVA ANTAGONIST AND SYSTEM FOR DIAGNOSING FATTY LIVER OR HEART FAILURE 有权

    公开(公告)号：US20230113511A1

    公开(公告)日：2023-04-13

    申请号：US17904702

    申请日：2021-02-26

    申请人： Lemin ZHENG ,  ProgLead, Inc

    发明人： Lemin ZHENG ,  Daowen WANG ,  Xiangbao MENG ,  Mingming ZHAO ,  Chenze LI

    IPC分类号： A61K31/205 ,  A61P1/16 ,  A61P9/00 ,  G01N30/72

    摘要： Use of a N,N,N-trimethyl-5-aminopentanoic acid antagonist in the preparation of a medicament for treating fatty liver or heart failure and a system for diagnosing fatty liver or heart failure. New treatment regimens are provided for fatty liver or heart failure. By antagonizing TMAVA, the levels of triglyceride and free fatty acids in the plasma and liver of a patient can be reduced, and at the same time, the inhibition effect of TMAVA on the activity of γ-isopropylbetaine hydroxylase can also be eliminated, and the weakening of free fatty acid mitochondrial β-oxidation caused by the decrease of endogenous carnitine synthesis is avoided. It is thus determined that reducing the ectopic accumulation of fatty acids in the liver and heart is clearly effective in treating fatty liver or heart failure.

    Risk markers for cardiovascular disease
    3.
    发明授权
    Risk markers for cardiovascular disease 有权
    心血管疾病风险标志

    公开(公告)号：US08722344B2

    公开(公告)日：2014-05-13

    申请号：US13683527

    申请日：2012-11-21

    申请人： Stanley L. Hazen ,  Michael Kinter ,  Marc S. Penn ,  Jonathan Smith ,  Lemin Zheng

    发明人： Stanley L. Hazen ,  Michael Kinter ,  Marc S. Penn ,  Jonathan Smith ,  Lemin Zheng

    IPC分类号： G01N33/53

    CPC分类号： G01N33/561 ,  C07K16/18 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/775 ,  G01N2800/32

    摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

    摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-I相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。

    Risk markers for cardiovascular disease
    4.
    发明授权
    Risk markers for cardiovascular disease 有权
    心血管疾病风险标志

    公开(公告)号：US08338110B2

    公开(公告)日：2012-12-25

    申请号：US12730137

    申请日：2010-03-23

    申请人： Stanley L. Hazen ,  Michael Kinter ,  Marc S. Penn ,  Jonathan Smith ,  Lemin Zheng

    发明人： Stanley L. Hazen ,  Michael Kinter ,  Marc S. Penn ,  Jonathan Smith ,  Lemin Zheng

    IPC分类号： G01N33/53

    CPC分类号： G01N33/561 ,  C07K16/18 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/775 ,  G01N2800/32

    摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

    摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。

    Risk markers for cardiovascular disease
    5.
    发明授权
    Risk markers for cardiovascular disease 有权
    心血管疾病风险标志

    公开(公告)号：US07781219B2

    公开(公告)日：2010-08-24

    申请号：US11005563

    申请日：2004-12-06

    申请人： Stanley L. Hazen ,  Michael Kinter ,  Marc S. Penn ,  Jonathan Smith ,  Lemin Zheng

    发明人： Stanley L. Hazen ,  Michael Kinter ,  Marc S. Penn ,  Jonathan Smith ,  Lemin Zheng

    IPC分类号： G01N33/53

    CPC分类号： G01N33/561 ,  C07K16/18 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/775 ,  G01N2800/32

    摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

    摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-I相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。

    Risk markers for cardiovacular disease
    6.
    发明申请
    Risk markers for cardiovacular disease 有权
    心肺疾病的危险标志物

    公开(公告)号：US20050239136A1

    公开(公告)日：2005-10-27

    申请号：US11005563

    申请日：2004-12-06

    申请人： Stanley Hazen ,  Michael Kinter ,  Marc Penn ,  Jonathan Smith ,  Lemin Zheng

    发明人： Stanley Hazen ,  Michael Kinter ,  Marc Penn ,  Jonathan Smith ,  Lemin Zheng

    IPC分类号： A61B20060101 ,  C07K16/18 ,  G01N33/53 ,  G01N33/68 ,  G01N33/92

    CPC分类号： G01N33/561 ,  C07K16/18 ,  G01N33/6893 ,  G01N33/92 ,  G01N2333/775 ,  G01N2800/32

    摘要： Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

    摘要翻译： 本文提供用于确定受试者，特别是人类受试者是否处于发展，具有或经历心血管疾病并发症的风险的方法，以及治疗由目前的心血管疾病风险的方法鉴定的受试者的方法。 在一个实施方案中，该方法包括确定来自受试者的身体样品中一种或多种氧化的载脂蛋白A-I相关生物分子的水平。 此外，提供了用于本方法的试剂盒和试剂。 还提供了用于监测受试者心血管疾病状态或治疗剂对心血管疾病受试者的影响的方法。 这种方法包括测定在受试者随时间或治疗之前或之后取自受试者的身体样品中一种或多种氧化的载脂蛋白A-1相关分子的水平。